Category: Markets
Published: 2026-07-16T12:59:36.000Z
Medtronic (NYSE: MDT) has completed its $650 million cash acquisition of SPR Therapeutics, adding the SPRINT® peripheral nerve stimulation (PNS) technology to its pain therapy portfolio. This acquisition expands Medtronic's offerings for minimally invasive, non-opioid treatments for chronic and acute pain, with clinical data showing significant pain reduction for patients using the 60-day SPRINT PNS system. The deal is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 and accretive thereafter, aligning with its strategy to pursue high-growth pain therapies.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.